TNDMHealthcare · Medical Devices

TNDM Stock Forecast: Tandem Diabetes Care, Inc. Price Predictions for 2026-2027

Last close, 11 Aug 2026

$23

+2.74% on the day

The 23 Wall Street analysts covering Tandem Diabetes Care, Inc. hold a median 12-month price target of $27 — +13.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 10 Aug 2026 — in the upper half.

Market cap

$1.5B

Ticker Nerd rank

58 / 100

Median analyst target

$27

Analysts covering

Total return, dividends reinvested

+16.0%

+52.1%

YTD

+6.6%

+131.7%

From 52W high

−17.1%

From 52W low

+131.7%

$10

$28

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

TNDM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tandem Diabetes Care, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Aug 2026

58 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth

Quality

Value

Volatility

Revisions

Accruals

Momentum

Size

Issuance

Growth (88): Sales and profits are climbing, and climbing faster than before.

Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.

Wall Street

TNDM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TNDM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says23 analysts

12 Buy11 Hold0 Sell

Low $18Median $27High $50

The green dot is the last close — the median target sits +13.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.

Date	Firm	Action	Rating	Target
7 Aug 2026	Citigroup	Maintains	Neutral	$17 → $21
7 Aug 2026	RBC Capital	Maintains	Outperform	$30 → $26
28 July 2026	UBS	Assumes	Neutral	$22 → $18
15 July 2026	Mizuho	Maintains	Neutral	$24 → $20
15 July 2026	Mizuho	Maintains	Neutral	—
23 June 2026	Deutsche Bank	Initiates	Hold	$16
23 June 2026	Deutsche Bank	Initiates	Hold	—
1 June 2026	Wells Fargo	Upgrade	Overweight	—
28 May 2026	Citigroup	Maintains	Neutral	—
18 May 2026	B of A Securities	Maintains	Neutral	—
12 May 2026	Benchmark	Initiates	Hold	—
11 May 2026	Barclays	Maintains	Overweight	—
11 May 2026	Truist Securities	Reiterates	Buy	—
20 Apr 2026	TD Cowen	Maintains	Buy	—
9 Apr 2026	Goldman Sachs	Maintains	Neutral	—
19 Mar 2026	Truist Securities	Upgrade	Buy	—
17 Mar 2026	Piper Sandler	Upgrade	Overweight	—
2 Mar 2026	Morgan Stanley	Maintains	Equal-Weight	—
23 Feb 2026	Lake Street	Upgrade	Buy	—
23 Feb 2026	Truist Securities	Reiterates	Hold	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TNDM appears on the weeks it earns a place.

Estimates

TNDM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Tandem Diabetes Care, Inc. (TNDM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −7.5×
Price / sales: 1.5×
Price / book: 11.6×
EV / EBITDA: −73.5×

Growth & margins

Revenue growth (YoY): 5.8%
Earnings growth (YoY): —
Gross margin: 56.9%
Operating margin: −5.4%
Net margin: −6.1%

Returns & dividend

Return on equity: −48.0%
Return on assets: −2.6%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TNDM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
TNDMTandem Diabetes Care, Inc.	$1.5B	58
CNMDCONMED Corp.	$1.5B	94
INSPInspire Medical Systems, Inc.	$1.7B	80
ATECAlphatec Holdings, Inc.	$1.4B	81
ENOVEnovis Corp.	$1.4B	82
IARTIntegra LifeSciences Holdings Corp.	$1.3B	89
ALMRAlamar Biosciences, Inc. (California)	$1.9B	4

The rank is the raw material. Whether the rules would actually own Tandem Diabetes Care, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TNDM news & analysis

Tandem Diabetes Care Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Tandem Diabetes Care reported second-quarter results featuring record sales, pump shipments, and gross margin for a second quarter. Management highlighted early progress in its transition to pharmacy-channel reimbursement and continued development of new insulin-delivery technologies.

Why it matters — TNDM watchers would note the record second-quarter sales and gross margin, alongside early progress on the pharmacy-channel reimbursement transition that could shape future growth.

Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Tandem Diabetes Care held its Q2 2026 earnings call, and Seeking Alpha published the transcript of the discussion with company executives.

Why it matters — Earnings call transcripts provide direct insight into Tandem's financial performance, operational updates, and management's outlook, which are key inputs for assessing the company's trajectory.

Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 7 Aug 2026neutral

Tandem Diabetes Care reported a Q2 loss of $0.31 per share, narrower than the Zacks Consensus Estimate of a $0.34 loss, and improved from the $0.48 per share loss in the prior-year quarter. Revenue lagged analyst estimates.

Why it matters — The loss per share beat consensus expectations yet revenue missed estimates, offering mixed signals about Tandem's quarterly performance for investors tracking TNDM.

Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research · 7 Aug 2026neutral

Zacks published a report examining Tandem Diabetes Care's (TNDM) Q2 (period ended June 2026) earnings, comparing its revenue and EPS against Wall Street estimates and year-ago figures, along with other key metrics.

Why it matters — A TNDM watcher would care because the review shows how the company's quarterly revenue and EPS stack up against analyst expectations and prior-year performance.

Tandem Diabetes Care Announces Second Quarter 2026 Financial Results

Business Wire · 6 Aug 2026positive

Tandem Diabetes Care reported financial results for the quarter ended June 30, 2026, with worldwide sales of $254.6 million, including $179.3 million in the U.S. It reported a gross margin of 57%, up 460 basis points versus the second quarter of 2025, and worldwide pump shipments of more than 33,000, including 22,000 in the U.S.

Why it matters — This quarterly report gives TNDM watchers the company's latest revenue, profitability and pump shipment figures, which signal real-world demand for its diabetes technology.

FAQ

Frequently asked questions about TNDM stock

What is the TNDM stock price forecast for 2026-2027?

The 23 Wall Street analysts covering Tandem Diabetes Care, Inc. have a median 12-month price target of $27, with estimates ranging from $18 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TNDM stock a buy right now?

Of the 23 analysts covering Tandem Diabetes Care, Inc., 12 rate it a Buy, 11 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tandem Diabetes Care, Inc. 58 out of 100 across roughly 4,600 US stocks as at 10 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TNDM?

As at 10 Aug 2026, Tandem Diabetes Care, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (88 of 100).

Will TNDM stock go up?

No one can know that. What the data says: the median 12-month target from 23 analysts implies +13.1% from the last close, and Ticker Nerd's factor model ranks Tandem Diabetes Care, Inc. 58 out of 100 as at 10 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TNDM stock forecast for 2030?

No analyst covering Tandem Diabetes Care, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNDM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $50 over the next 12 months.

How has TNDM stock performed over the past year?

Tandem Diabetes Care, Inc. returned +131.7% over the 12 months to 11 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tandem Diabetes Care, Inc. do?

What is the latest news on TNDM?

The most recent item we track (MarketBeat, 7 Aug 2026): "Tandem Diabetes Care Q2 Earnings Call Highlights". Tandem Diabetes Care reported second-quarter results featuring record sales, pump shipments, and gross margin for a second quarter. Management highlighted early progress in its transition to pharmacy-channel reimbursement and continued development of new insulin-delivery technologies.

Company

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care designs, develops, and commercializes advanced technology solutions for insulin-dependent diabetes management worldwide. The company's flagship products are the t:slim X2 insulin pump and the Tandem Mobi automated insulin delivery system, both featuring Control-IQ or Control-IQ+ hybrid closed-loop technology that helps optimize blood glucose levels. These durable insulin pumps work alongside continuous glucose monitoring systems, including integration with Abbott's FreeStyle Libre 3 Plus sensor. Tandem also manufactures disposable products such as infusion sets and cartridges for insulin storage and delivery. Nearly three-quarters of revenue derives from the United States, with the remainder primarily from other developed nations. The company serves individual patients with insulin-dependent diabetes across multiple distribution channels, including direct sales, pharmacy partnerships, and healthcare providers. Founded in 2006 and headquartered in San Diego, California, Tandem operates as a global leader in automated insulin delivery technology.

CEO Mr. John F. Sheridan · 2,500 employees · United States · https://www.tandemdiabetes.com